Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00212836
Status:
COMPLETED
Last Update Posted:
2022-02-16
First Post:
2005-09-13
Brief Title:
Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia 25543COMPLETEDP05817
Sponsor:
Organon and Co
Organization:
Organon and Co
Study Overview
Official Title:
A Multicenter Double-Blind Flexible -Dose 6-Month Trial Comparing the Efficacy Safety of Asenapine With Olanzapine in Stable Subjects With Predominant Persistent Negative Symptoms of Schizophrenia
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Treatment with conventional antipsychotics such as haloperidol has little effect or may sometimes even worsen negative symptoms such as blunted affect emotional withdrawal and poor rapport of schizophrenia The newer atypical antipsychotics agents such as olanzapine have shown improvement in the treatment of negative symptoms in acute trials The purpose of this study is to compare an investigational compound asenapine with a marketed agent olanzapine in the treatment of stable subjects with persistent negative symptoms of schizophrenia for 6 months Patients completing this study may be eligible to participate in an extension 6 months of treatment Patients are required to have stable symptoms prior to entry into study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 25543 | None | None | None |
| Aphrodite | None | None | None |